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Summary 
In yeast strains bearing the point mutation called 
GAL11P (for potentiator), certain GAL4 derivatives 
lacking any classical activating region work as strong 
activators. The P mutation confers upon GALl1, a 
component of the RNA polymerase II holoenzyme, the 
ability to interact with a portion of the dimerization 
region of GAL4. The region of GALl1 affected by the 
P mutation is evidently functionally inert in ordinary 
cells, suggesting that this mutation is of no functional 
significance beyond creating an artificial target for the 
GAL4 dimerization fragment. From these observations 
and further analyses of GALl 1, we propose that a sin- 
gle activator-holoenzyme contact can trigger gene ac- 
tivation simply by recruiting the latter to DNA. 
Introduction 
According to our current picture, gene activation requires 
interaction of DNA-bound activators with proteins binding 
near the transcription start site of a gene. A typical tran- 
scriptional activator bears distinguishable DNA-binding 
and activating regions (Ptashne, 1988). In eukaryotes, 
activation of polymerase II genes requires, in addition to 
RNA polymerase, many transcription factors, and activat- 
ing regions have been shown to contact one or another 
of these, including TATA-binding protein (TBP), TBP- 
associated factors (TAFs), TFIIB, and TFIIH (Roeder, 
1991 ; Zawel and Reinberg, 1993; Conaway and Conaway, 
1993; Hoey et al., 1993). One strong activating region (that 
found on virion protein 16 [VP16]) has been reported to 
contact all of these four proteins (Stringer et al., 1990; Lin 
et al., 1991 ; Goodrich et al., 1993; Xiao et al., 1994). These 
findings, taken with the results of a wide array of experi- 
ments performed in vitro, have led to the suggestion that 
transcriptional activation involves a multistep assembly 
process, various steps of which might be catalyzed by 
activators (Buratowski et al., 1989; Choy and Green, 1993). 
It has been proposed, for example, that activating regions 
recruit one or more of these factors to DNA, or cause 
crucial conformational changes in target proteins that initi- 
ate the complex process of assembling the transcriptional 
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apparatus, or do both (Lin and Green, 1991; Roberts and 
Green, 1994; Hori and Carey, 1994). An alternative and 
simpler scenario has been suggested by the finding that 
in yeast, RNA polymerase II and multiple transcription fac- 
tors associate in the absence of DNA to form a so-called 
holoenzyme (Koleske and Young, 1994; Kim et al., 1994). 
According to that scenario, recruitment of the holoenzyme 
would suffice for gene activation (Koleske and Young, 
1994; Carey, 1994). 
The experiments reported here describe a specific in- 
stance of gene activation in yeast that is consistent with the 
latter picture. Our experiments identify a single protein, 
protein interaction that triggers gene activation. We show 
that a point mutation converts an apparently inert surface 
of a component of the holoenzyme into a new and evidently 
arbitrary interaction site for a peptide that is devoid of any 
classical activating function. A fusion protein bearing this 
latter peptide attached to a DNA-binding domain is a 
strong transcriptional activator that works only in cells 
bearing the new target. The simplest explanation for these 
results, when considered with further analyses of the novel 
target protein, is that interaction between a DNA-bound 
protein and a single component (perhaps any component) 
of the holoenzyme can recruit the latter to DNA and 
thereby activate gene transcription. 
Our findings arose from our attempts to explain the prop- 
erties of a yeast mutant in which certain weak derivatives 
of the transcriptional activator GAL4 work as strong activa- 
tors (Himmelfarb et al., 1990). The yeast mutant bears a 
single amino acid change in the protein GALl1 to form 
GAL11P (for potentiator). The mutation changes Asn to 
lie at position 342 of this 1081 amino acid protein (see 
legend to Figure 6). We show, using a combination of ge- 
netic and biochemical analyses, that the mutation in 
GALl 1P, which lies in a functionally inert part of the pro- 
tein, promotes a novel interaction between GALl1 and 
a segment of the dimerization region (not the activating 
region) of GAL4. We confirm the finding that GALl1 is 
part of the holoenzyme, and we propose that the GALl 1P- 
GAL4 interaction recruits the holoenzyme and thereby trig- 
gers gene activation. A prediction of this model is that 
wild-type GALl 1 fused to a DNA-binding domain activates 
transcription by interacting with its partners in the holoen- 
zyme, and we present experiments upporting this idea. 
Results 
Our experiments utilize a variety of protein fragments, 
some of which are analyzed as fusions. These include 
GAL4 derivatives that contain at least residues 1-93 and 
ranging up to residues 1-100, all of which contain DNA- 
binding and dimerization domains but no activating re- 
gions; GAL4(1-147), which also forms DNA-binding di- 
mers and does not activate transcription in yeast; 
GAL4(74-881), which contains two activating regions but 
does not bind DNA (Ma and Ptashne, 1987; Reece and 
Ptashne, 1993); PPR1 (for pyrimidine pathway-regulatory 
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191 bp , , , GAL1-1ac~ 
Activator binding 
sites 
-qal activity 
Activator gal l  1" GALl 1- GALl 1P 
GAL4(1-881) 640 2850 3225 
GAL4(1-147)+AH 33 135 1921 
LexA(1-202)+AH 17 58 44 
GCN4 128 691 623 
Figure 1. The Effects of GALl1 and GALl 1P on Different Activators 
Three otherwise isogenic derivatives of strain FY250 (a gift of F. Win- 
ston) were constructed carrying a low copy plasmid containing either 
GALll, GAL11P, or no GALl1 allele. Each strain also bore a second 
low copy plasmid expressing the indicated transcriptional activator 
from the ACT1 promoter. Each strain was deleted for the chromosomal 
GAL4 and GALl1 genes, and the depicted reporter was integrated at 
the URA3 locus. The strain used to measure the activity of GCN4, 
which activates many amino acid biosynthetic genes, was also deleted 
for the chromosomal GCN4 gene. In this and the other figures of this 
paper, activity is given in units of I~-galactosidase activity per amount 
of protein in a whole-cell extract. 
1), a close relative of GAL4 with DNA-binding and dimer- 
ization domains (but no activating region) in residues 29-  
123 (Marmorstein and Harrison, 1994); PUT3, another 
close relative of GAL4 with DNA-binding and dimerization 
(but no activating regions) in residues 31-100 (Reece and 
Ptashne, 1993); LexA, a 202 amino acid bacterial repres- 
sor, the first 87 amino acids of which contain the DNA- 
binding domain (Ruden et al., 1991); AH (for amphipathic 
helix), a synthetic 15 amino acid peptide that confers a 
weak activating function to a DNA-binding molecule; and 
SH (for scrambled helix), a related sequence that lacks 
the activating function (Giniger and Ptashne, 1987). 
GAL l  1 
GALl1 was originally identified as a protein required for 
efficient galactose utilization in yeast (Nogi and Fukasawa, 
1980). We and others showed that in cells deleted for 
GALl1, activation by GAL4 is reduced some 3- to 5-fold. 
This effect cannot be accounted for by decreased levels 
of the activator, because overexpression of GAL4 does not 
overcome the GALl  1 requirement for full activation (Him- 
melfarb et al., 1990; Suzuki et al., 1988; Long et al., 1991). 
Figure 1 shows four activators, GAL4, GAL4(1-147)+AH, 
LexA(1-202)+AH, and GCN4, the latter two of which are 
unrelated to GAL4, that require GALl1 for full activity. 
Thus, contrary to our original surmise (Himmelfarb et al., 
1990), at least some activators lacking GAL4 sequences, 
as well as GAL4-derived activators, require GALl  I for full 
activity. Consistent with this view is the fact that gall1 
mutants have been isolated in screens involving transcrip- 
tion of genes unrelated to the GAL genes (Fassler and 
Winston, 1989; Vallier and Carlson, 1991 ; S. J. Kron and 
G. R. Fink, personal communication). Sakurai et al. (1993) 
have reported that, in vitro, omission of GALl  I decreases 
basal transcription (i.e., transcription seen in the absence 
of activators). These results, taken together, suggest that 
GALl1 is part of the transcriptional apparatus that is re- 
quired for full activity at many yeast promoters. In experi- 
ments performed in vivo, we typically assay the function 
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Figure 2. GALl 1 Is a Component of the RNA Polymerase II Holoen- 
zyme 
(A) GALl I coimmunoprecipitates with SRB4, a component of the holo- 
enzyme. Yeast whole-cell extracts containing no GALl 1 protein (mi- 
nus), or Myc epitope-tagged GALl I wild-type (wt) or GALl 1P (P) pro- 
teins, were incubated with monoclonal antibodies directed against the 
Myc epitope. I mm unoprecipitates w re collected by addition of protein 
G-Sepharose beads. Precipitates (Pellet) and supernatants (Sup.) 
were subjected to SDS-PAGE, transferred to a nitrocellulose filter, 
probed with anti-SRB4 antibodies, and visualized by chemilumines- 
cence (Amersham). Molecular weight standards are indicated in kilo- 
daltons. 
(B) GALl 1 is present in purified holoenzyme. A holoenzyme prepara- 
tion (1 lig and 2 I~g) enriched - 1000-fold from nuclear extract of yeast 
cells containing GALl 1 wild-type (wt) protein (a gift of A. Koleske and 
R. Young) was subjected to SDS-PAGE (lanes 1 and 2) along with 
200 p.g of nuclear extracts of gall 1- (lane 3) and GAL 11 wild-type (lane 
4) cells. The gel was blotted onto a nitrocellulose filter, probed with 
antibodies to GALl 1, and visualized by chemiluminescence (panel 1). 
The GALl 1 antibodies were then removed and the filter reprobed with 
SRB4 antibodies (panel 2). The procedure was repeated with antibod- 
ies to RPB1, the largest subunit of yeast RNA polymerase II (panel 
3). Molecular weight standards are indicated in kilodaltons. 
of activator-stimulated promoters, and so the effect of 
GALl1 is detected as an effect on gene activation. We 
emphasize, however, that there is no evidence suggesting 
that GALl  1 is the target of any natural transcriptional acti- 
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vating region, and that its effect is not restricted to genes 
or activators involved in galactose metabolism. 
Figure 2 shows that GALl1 is found exclusively, or 
nearly so, as part of the RNA polymerase II holoenzyme. 
This holoenzyme complex, as isolated by Koleske and 
Young (1994), comprises at least 30 proteins, including 
RNA polymerase II, the general transcription factors 
TFIIB, TFIIF, and TFIIH, and at least four SRB (for suppres- 
sor of RNA polymerase B) proteins. Figure 2A shows that 
precipitation from a nuclear extract of Myc-tagged GALl 1 
with a Myc antibody coprecipitates SRB4, a component 
of the holoenzyme. The precipitate also contains SRB5 
(data not shown). The first panel of Figure 2B shows that 
the holoenzyme purified and characterized by Koleske and 
Young (their gift) contains GALl1. This experiment was 
performed by subjecting purified holoenzyme to SDS- 
polyacrylamide gel electrophoresis (SDS-PAGE) and then 
immunoblotting with antibodies raised against GALl1. 
Scanning densitometry analysis of the autoradiogram sug- 
gests that the amount of GALl 1 present in 1 I~g of holoen- 
zyme (lane 1) is about 7-fold greater than the amount found 
in 200 I~g of a GALl 1 + nuclear extract (lane 4). Taken with 
the degree of purification of the holoenzyme used in this 
experiment (about 1000-fold from nuclear extracts), this 
result suggests that most or all of the GALl 1 in the nucleus 
is in the holoenzyme. This conclusion is supported by the 
results of an experiment in which the same filter probed for 
GALl 1 (Figure 2B, first panel) was successively washed 
and reprobed for SRB4 (second panel) and then for RPB1, 
the largest subunit of yeast RNA polymerase II (third 
panel). Thompson and Young (1995) have deduced that 
SRB4 is found exclusively, or nearly so, in the holoen- 
zyme, whereas a large fraction of RNA polymerase II is 
not. Lanes 1, 2, and 4 of the first and second panels indi- 
cate that in this experiment, the fraction of SRB4 that is 
recovered in the holoenzyme is indistinguishable from the 
fraction of GALl I so recovered. In contrast, the third panel 
reveals that, as expected, a much smaller fraction of RNA 
polymerase II is present in the holoenzyme. These results 
are also consistent with the finding of Kim et al. (1994) 
that GALl 1 is part of their so-called mediator complex that 
associates with RNA polymerase II. 
GALl 1P 
In contrast with the requirement for wild-type GALl1 for 
full activation by many activators, the mutant GALl 1P po- 
tentiates the activities of certain weak GAL4 derivatives 
only. Thus, for example, the activity of GAL4(1-147)+AH 
is some 10- to 100-fold higher in GALl 1P than in wild-type 
cells (see, for example, Figure 1, line 2; Himmelfarb et al., 
1990, Table 1). As shown in line 1 of Figure 1, native GAL4 
is not potentiated when assayed on a reporter bearing 
consensus GAL4-binding sites. However, when binding 
of GAL4 is impaired by mutation either of the DNA site or 
of the protein, and activation thereby weakened, potentia- 
tion is observed (Himmelfarb et al., 1990; data not shown). 
Figure 1 also shows that two other activators lacking GAL4 
sequences (LexA(1-202)+AH and GCN4) are unaffected 
by GALl 1P. Each of these activators works indistinguish- 
ably in GALl1  wild-type and GAL11P cells, and less well 
LexA 
sites 
50 bp ' I GALI-Iac~ 
TATA I 
B-oal activity 
Activator GALl 1 * GALl 1 P 
LexA(1-202)+GAL4(58-93) <1 <1 
(58-95) <1 <1 
(58-96) <1 96 
(58-97) <1 1052 
{58-147)+AH 65 2304 
B 
, 191 bp ' I GALl -lac~ 
] ~ TATA ] 
.B-gal ~ c.tivi1~. 
ActNator GALl 1 + GALl 1P 
- -  <1 <1 
GAL4(1-93) <1 <1 
(1-95) <1 <1 
(1-96) <1 152 
(1-97) <1 1820 
(1-147)+AH 248 1498 
LexA 
sites 
50 bp I GALI-Iac~ 
T^ TA I 
B-gal aclivilv 
Activator GALl 1 * GALl 1P 
LexA(t -202)+GAL4(50-147)+AH 82 1103 
R63G 87 578 
Q66R 48 142 
Figure 3. GAL4 Residues 58-97 Constitute an Activating Region in 
GALl 1P Cells 
(A) GAL4(58-97) fused to LexA activates in GAL11P cells. The indi- 
cated fusion proteins were expressed from the ACT1 promoter on a 
low copy plasmid. GALl1 proteins were expressed from the GALl1 
promoter on low copy plasmids. The strain used in these experiments 
is JPY42 and is ga/4- and ga/11-. The integrated reporter template 
has two LexA-binding sites positioned 50 bp upstream of the GALl 
TATA box. 
(B) GAL4 residue 97 is the carboxyl border of the novel activating 
region. Deletion derivatives of GAL4 were expressed from the ACT1 
promoter on a low copy plasmid. GALl1 alleles were those described 
in (A). The strain used in these experiments is JPY16 and is gal4- and 
gall1-. The integrated reporter template has the UASG (an element 
that includes the GAL4-binding sites) at its native position upstream 
of the GALl TATA box. 
(C) Mutations in GAL4(58-97) impair the novel activating region. 
LexA(1-202)+GAL4(50-147)+AH, bearing either no mutations or the 
indicated amino acid substitutions, was expressed from the ACT1 pro- 
moter on a low copy plasmid. GALl 1 alleles were those described in 
(A). The strain used in these experiments i  JPY42. 
in ga l l1 -  cells. In a previous publication, we reported that 
the yeast activator PPR1 (which bears a DNA-binding do- 
main similar to that of GAL4) responded to GALl 1P (Him- 
rnelfarb et al., 1990). We believe this result to have been 
incorrect; we now find that PPR 1 and the weakly activating 
derivative PPR1(1-123)+AH have the same activity in 
GAL l1  wild-type and GAL l lP  cells (data not shown). 
In the following paragraphs, we first show that part of 
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Tagged (261-351 P)+(799-1081 } 2930 
Figure 4. Mini-GALl1 Deletion Derivatives Work Nearly as Efficiently 
as the Full-Length Proteins 
GALl1 and GALl 1 derivatives were expressed from the GALl1 pro- 
moter on a low copy plasmid. GAL4(1-147)+AH was expressed from 
the ACT1 promoter on a low copy plasmid. The strain used in this 
experiment (YT6) is gal4- and gall1-. The indicated reporter gene, 
which has the UAS~ at its native position upstream of the GALl TATA 
box, was integrated at the URA3 locus. 
the dimerization domain of GAL4 works as an activating 
region in GAL 11P cells; second, demonstrate in vitro that 
this fragment of GAL4 interacts specifically with GALl 1 P; 
third, analyze changes in GALl 1 that confer the GALl 1P 
phenotype; and fourth, argue that the region of GALl1 
that bears the site of the GAL11P mutation is ordinarily 
functionally inert. 
GAL4(58-gz) Activates Transcription 
in GAL11P Cells 
As shown in Figure 3A (line 4), LexA+GAL4(58-97) cannot 
activate a gene bearing LexA-binding sites in wild-type 
cells, but in GALl 1P cells, this fusion protein functions as 
a very strong activator of such a gene. We i m plicated GAL4 
residues (58-97) by the following deletion analyses. As 
shown in Figu re 3B, GAL4(1-97) strongly activates a gene 
bearing GAL4-binding sites in GAL11P cells but not at all 
in wild-type cells; GAL4(1-95) activates in neither cell; and 
GAL4(1-96) activates to an intermediate level, and only 
in GAL11P cells. GAL4(1-100) activates transcription as 
strongly as GAL4(1-97) in GALl 1P cells (data not shown). 
Each of these proteins is expressed and, as assayed in 
cell extracts, binds DNA with similar efficiency (data not 
shown). These results define the carboxyl border of the 
novel activating region to be residue 97. Figure 3A shows 
that the same carboxyl border is observed with GAL4 pep- 
tides fused to LexA and assayed on a gene bearing LexA 
sites in a GAL11P cell. The amino border of the activating 
element evidently lies near residue 58, because deletion 
of four amino-terminal residues to form, for example, Lex- 
A+GAL4(62-97), inactivates each of the derivatives in Fig- 
ure 3A (data not shown). 
The conclusion that GAL4 residues 58-97 carry the 
GALl 1 P recognition site is further supported by the follow- 
ing observation. We mutagenized a LexA-GAL4 deriva- 
tive bearing the activating region AH and found two mu- 
tants that activated normally or nearly so in wild-type cells 
but that, compared with the parent, were impaired for acti- 
vation in GAL11P cells. These mutations substituted Gly 
for Arg at position 63 and Arg for Gin at position 66; their 
effects are shown in Figure 3C. 
Residues 58-97 comprise part of the dimerization r~e - 
gion of GAL4. The crystal structure ofGAL4(1-65) reveals 
a coiled coil that originates at residue 50 and continues 
through residue 64 (Marmorstein et al., 1992). We do not 
know whether this coiled coil continues uninterrupted 
through residue 97. 
In Vitro, Peptides Containing GAL4 Residues 58-97 
Interact with GAL l lP  but Not with GALl1 
To study the GAL4-GAL11P interaction in vitro, we puri- 
fied a shortened (so-called mini) form of GALl 1 (compris- 
ing residues 261-351 plus 799-1081) with or without the 
P mutation at residue 342. Each of these derivatives also 
contains a run of 6 His residues and a 10 amino acid Myc 
epitope at its amino terminus. Mini-GALl 1 works about as 
well as does full-length GALt 1 in helping GAL4 to activate 
transcription (Figure 4, lines 1 and 4), and mini-GALl1P 
works about as well as full-length GAL11P in helping 
GAL4(1-147)+AH to activate (Figure 4, lines 3 and 5). The 
binding experiment was performed by attaching either of 
these tagged GALl1 or GALl 1P proteins to a newly de- 
signed chip displaying nickel atoms (G. S., C. B., A. B., 
J. Strominger, and G. Whitesides, unpublished data) 
and testing for their interaction with eight purified pro- 
teins in a BIAcore instrument (Chaiken et al., 1992). The 
following five proteins, each of which bears GAL4 residues 
58-97, bound to mini-GAL11P: GAL4(1-147)+AH, 
GAL4(1-147)+SH, PUT3(31-79)+GAL4(58-100), GAL4 
(1-100), and GAL4(1-147); data for the first three of these 
proteins are shown in Figures 5A, 5B, and 5C. In contrast, 
the following proteins, each of which lacks part or all of 
GAL4(58-97), failed to bind to GALlt  P: GAL4(1-94), 
PPR1(29-123), and PUT3(1-100)+AH (Figures 5A and 
5B). Mini-GALl1 wild type did not bind significantly to 
PUT3(1-100)+AH, GAL4(1-147)+AH, or GAL4(1-147), as 
shown in Figure 5D. The two forms of mini-GALl1 inter- 
acted equally well with Myc antibodies, and a mixture con- 
taining equal amounts of mini-GALl 1 wild type and mini- 
GAL11P bound various proteins bearing GAL4(58-97) 
(data not shown). 
Substitution of Various Hydrophobic Residues 
for Asn at Position 342 Creates 
the GAL l l P  Phenotype 
As previously noted, the original GALl 1P mutant bore an 
lie residue at position 342 (Himmelfarb et al., 1990). Ran- 
domization of codon 342 revealed that substitution with 
other hydrophobic residues yields the GALl 1 P phenotype 
to different extents. Thus, as shown in Figure 6, Leu or 
Val at position 342 mimics the effect of lie at that position 
(Val conferring in fact a stronger effect when assayed with 
LexA+GAL4(58-97), a molecule that lacks a classical acti- 
vating region), and Met or Thr confers a somewhat weaker 
effect. 
The effect of GALl 1P is not readily mimicked by muta- 
tion elsewhere. We reached this conclusion by repeating 
with some modifications the original screen of Himmelfarb 
et ai. (1990), using an activator, GAL4(1-238), that bears 
only one of the two principal activating regions of GAL4 
(Ma and Ptashne, 1987). We found that of 15 mutations 
unlinked to the activator gone, all were mutated to lie at 
residue 342 of GALl I (Reinagel, 1994). The other substitu- 
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Figure 5. Proteins Containing GAL4(58-97) Interact with GALl 1P but 
Not with GALl1 Wild Type 
Interactions were detected by surface plasmon resonance in a BIAcore 
Activator binding 
sites 
I GALl -lac~ 
TATA I 
J~-.ga.I activity 
GAL4(1 -147)  LexA(1-202) 
GAL l  1 altele +AH +GAL4{58-97) 
- -  26  < I  
Posit ion 342 Asn(WT) 1 03 <1 
lie (GALl  1 P) 3304 950 
Val 3207 2060 
Leu 2463 713 
Thr 10"~4 114 
Met 121 i 121 
Gly 1 03 <1 
Trp 115 <I  
Asp 112 <1 
&(337-347) 107 ND 
Figure 6. Hydrophobic Amino Acids at Position 342 of GALl 1 Confer 
the GALl 1P Phenotype 
The strains used for the experiments of column one (YT6) and for 
those of column two (JPY42) were both deleted for GALl1 and for 
GAL4. YT6 carried an integrated reporter with UASG at its normal 
position upstream of the GALl TATA box, and JPY42 carried a similar 
reporter but with two LexA-binding sites 50 bp upstream of the TATA 
box. The activator GAL4(1-147)+AH was integrated into the YT6 
strain, and the activator LexA(1-202)+GAL4(58-97) was introduced 
on a low copy plasmid into JPY42. For the experiments on each line, 
a low copy plasmid expressing the indicated GALl1 allele was intro- 
duced into both strains. The GALl1 alleles encoding Met, Thr, Leu, 
and Val at position 342 were recovered from a screen of candidates 
generated by randomization of codon 342, and the alleles encoding 
Gly, Trp, Asp, or the deletion A(337-347) were generated by site- 
directed mutagenesis. The GALl 1P mutation was originally assigned 
to position 225 on the basis of the GALl1 sequence in Suzuki et al. 
(1988) and is new renumbered according to the corrected sequence 
in the published erratum for Suzuki et al. (1988). 
instrument (Pharmacia), where the net change in the baseline from 
before to after sample injection, in resonance units (RUs), indicates 
binding of proteins to a surface-immobilized target protein. Note that 
peaks represent changes due to factors other than net binding, such as 
a different refractive index of the sample buffer. X indicates resonance 
signals measured before and after injections. The tables below the 
sensograms display the RU values as calculated by the BIAcore instru- 
ment at the time indicated by the number of the X. ARU values are 
obtained by subtracting the RU measured before injection from the 
RU measured after injection of each sample. 
(A) GAL4(1-147)+AH, but not GAL4(1-94), binds to immobilized mini- 
GAL11P. The experiment was performed by first immobilizing mini- 
GALl 1P to the nickel-coated chip surface followed by sequential injec- 
tion of the other proteins at the indicated concentrations. Experiments 
in which only GAL4(1-147)+AH was injected subsequent to the His- 
tagged protein gave effectively the same results (data not shown). 
(B) PPR1(29-123) and PUT3(1-100)+AH do not significantly bind to 
mini-GAL11P, whereas GAL(1-147)+SH does. The experiment was 
performed as in (A), with the proteins injected at the indicated concen- 
trations. The sensorgram indicating binding of mini-GAL11P to the 
nickel-coated chip is not shown. 
(C) A fragment of the GAL4 dimerization region fused to the DNA- 
binding domain of PUT3 confers to this molecule the ability to interact 
with mini-GAL11P. As in (B), PUT3(1-100)+AH is unable to interact 
with mini-GALl 1P. Binding of mini-GALl 1P to the nickel-coated chip 
is not shown. 
(D) Various DNA-binding proteins, including GAL4 derivatives, do not 
significantly bind to mini-GALl I wild type. The ARU values are typical 
of nonspecific binding to the chip surface. The experiment was carried 
out as in (A). Binding of mini-GALl 1 wild type to the chip is not shown. 
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Figure 7. TheTranscriptionalActivating Region ofGALll Is Essential 
for GALl I Function and Is Part ofthe RNA Polymerase II Holoenzyme 
(A) The principal activating region of GALl 1 resides in the carboxyl 
terminus. Deletion derivatives of LexA-GAL11 were expressed from 
the ADHI promoter on a low copy plasmid. The strain used in these 
experiments, J PY17, is gall 1- and gal4- and bears a chromosomally 
integrated reporter harboring twoLexA operators at the position indi- 
cated. 
(B) The carboxyl region of GALl1 interacts with components of the 
holoenzyme. Monoclonal antibodies directed against a Myc epitope 
were incubated with extracts of yeast cells carrying either no GALl1, 
GALl 1 wild type, or the indicated epitope-tagged GALl 1 derivatives 
(plus). Proteins precipitated with Sepharose G beads (Pellet), as well
tions that yield strong potentiation (i.e., Leu or Val) were 
presumably not obtained, because, unlike replacing Asn 
with lie, those substitutions require multiple base changes. 
Reconstruction experiments how that GALl  1 bearing Thr 
or Met at position 342 would not have scored as GALl  1 P 
in this experiment. 
The Region Including and Flanking Residue 342 in 
Wild-Type GALl1 Does Not Engage in Any 
Crucial Protein-Protein Interaction 
As shown in Figure 6, GALl1 mutants bearing Gly, Asp, 
or Trp at position 342 behave indistinguishably from wild- 
type GALl1.  The figure also shows that deletion o f  resi- 
dues 337-347 has no effect on the activity of wild-type 
GALl  1. These results support the idea that the GALl 1P 
mutation has introduced an entirely novel function to the 
protein, making it the fortuitous target of a peptide that 
otherwise has no activating function. 
LexA-GAL11 
GALl 1 fused to LexA and bound to LexA sites is an extraor- 
dinarily powerful activator of transcription in yeast (Himmel- 
farb et al., 1990). When compared using reporters differing 
only in the nature of activator-binding sites positioned 
about 100 bp upstream of the TATA box, LexA-GAL11 and 
LexA-GAL11P activated indistinguishably and at least as 
strongly as did GAL4, itself a very strong activator in yeast 
(Himmelfarb et al., 1990; data not shown). More recent 
experiments in which the activators were positioned some 
1200 bp upstream of the TATA box revealed that LexA- 
GALl 1 activated some 10- to 20-fold more efficiently than 
LexA-GAL4 (L. Gaudreau, V. Goldburt, and M. P., unpub- 
lished data). The facts that GALl1 is part of the holo- 
enzyme and that GAL11P is the target of GAL4(58-97) 
suggest that LexA-GAL11 activates transcription by inter- 
acting with its ordinary partners in the holoenzyme. Ac- 
cording to this idea, LexA-GAL11 does not bear a classical 
activating region; rather, it forms part of the holoenzyme 
and, by binding to DNA through its LexA moiety, recruits 
the holoenzyme to the template. The notion that LexA- 
GALl1 forms part of the holoenzyme is highly plausible 
in view of the finding that LexA-GAL11 functions as effi- 
ciently as does wild-type GALl1 in helping (for example) 
GAL4 to activate transcription (see Figure 7C, lines 1 and 
7; Himmelfarb et al., 1990). We infer that activation by 
as proteins present in the supernatant (Sup.), were analyzed by immu- 
noblotting with antibodies directed against SRB4, a component of th  
holoenzyme. 
(C) The carboxyl region of GALl 1 is necessary and sufficient forGALl 1 
activity. Derivatives of GALl1 were expressed from the GALl1 pro- 
moter on a low copy vector. The strain, JPY14, is isogenic to JPY17, 
except that it is GAL4 ÷, and the integrated reporter contains a UASa 
at its natural p~osition i  the GALl promoter. 
(D) Overexpression of GALl1 squelches activation by LexA-GAL11 
but not activation by LexA-GAL4. The activities of LexA-GAL11 and 
LexA-GAL4 were determined in strain JPY27, which is gal4-. The 
activators were expressed from the ADH1 promoter on a low copy 
vector. The reporter gene shown as integrated at the URA3 locus. 
GALl1 was overexpressed by introducing a high copy plasmid ex- 
pressing GALl1 from its own promoter. 
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DNA-bound LexA-GAL11 is similar to that effected by the 
interaction of DNA-bound GAL4(1-97) with GAL11P, the 
salient difference being that in the case of LexA-GAL11 (or 
LexA-GAL11P), the relevant surface of GALl I is tethered 
covalently to the LexA DNA-binding domain. The following 
three lines of argument further support this view. 
First, the activating region of GALl 1 interacts with com- 
ponents of the holoenzyme. Figure 7A shows that the acti- 
vating region on GALl1 is contained primarily within its 
carboxy1282 residues. Thus, LexA+GAL11(799-1081) ac- 
tivates nearly as strongly as does LexA-GAL11 (compare 
lines 2 and 5 of Figure 7A), whereas derivatives lacking 
this region activate much less efficiently (Figure 7A, lines 
3 and 4). Figure 7B shows that two GALl1 derivatives 
containing this carboxyl region coimmunoprecipitate with 
SRB4, a component of the holoenzyme, but that two 
GALl 1 derivatives lacking this carboxyl region do not. All 
four GALl 1 derivatives were expressed at similar levels, 
as determined by Western blot (data not shown). 
Second, the activating region of LexA-GAL11 also pro- 
vides a significant portion of the ordinary activator-helping 
function of GALl 1. Thus, as shown in Figure 7C, the car- 
boxyl 282 residues of GALl 1 that are required for strong 
activation by LexA-GAL11, as determined in the experi- 
ment summarized in Figure 7A, are also required for the 
normal activity of GALl 1, as determined in the experiment 
summarized in Figure 7C, lines 1,2, and 3. Moreover, this 
carboxyl fragment of GALl1, both on its own and as a 
LexA fusion, provides about 60% of the helping effect of 
GALl 1 (Figure 7C, lines 6 and 8; data not shown), presum- 
ably because it plays its ordinary role in the holoenzyme 
relatively efficiently. 
Third, GALl 1 squelches activation by LexA-GAL11 but 
not that elicited by LexA-GAL4. The experiment shown 
in Figure 7D argues that the target contacted by the acti- 
vating region on LexA-GAL11 differs from the site(s) con- 
tacted by a classical activating region, a result consistent 
with the idea that LexA-GAL11 contacts its bona fide part- 
ners in the holoenzyme when working as an activator. 
Thus, overexpression of GALl1 decreases (squelches) 
(Gill and Ptashne, 1988; Ptashne, 1988) activation by 
LexA-GAL11 but not by LexA-GAL4, an effect that is most 
simply understood as a consequence of saturation of the 
GALl 1 site in the complex with the overexpressed GALl 1. 
Such a saturation would prevent further interaction of 
DNA-bound LexA-GAL11 with its partners but would have 
no effect on the interaction of DNA-bound LexA-GAL4 
with its target, whatever that might be. 
Discussion 
Our principal conclusions are represented in Figure 8. 
Substitution with any of several hydrophobic residues at 
position 342 of GALl 1, a component of the RNA polymer- 
ase II holoenzyme, creates a novel site for interaction with 
a portion of GAL4. This region of GAL4 (included in resi- 
dues 58-97) is part of its dimerization domain, and, 
whether as part of GAL4 or when fused to LexA as shown 
in Figure 8A, it has no activating function in wild-type cells. 
In the presence of GALl 1P, however, the residues work 
as a powerful activating region, presumably by recruiting 
the holoenzyme to DNA (Figure 8B). As predicted by this 
model, and as shown in Figure 8C, GALl1 itself, when 
fused to a DNA-binding domain, works as a strong activa- 
tor. These pictures should be considered along with the 
following considerations. 
The simplest explanation for our results is that the gene 
activation we describe is effected by recruitment of the 
holoenzyme to DNA. A contrasting idea would be that in- 
teraction between GAL4(58-97) and GALl 1P introduces 
(for example) some conformational effect (e.g., that pro- 
posed to be the result of VP16-TFIIB interaction [Roberts 
and Green, 1994]) or some enzymological modification 
that would be required to trigger gene activation. The re- 
cruitment idea is strongly suggested by our findings that 
A 
Gat4(58-97}~ 
LexA 
i ~Jx 
WT Cells 
holoenzyrne 
TATA I 
No Activation 
B GALl 1P Cells 
G a J 4 ( ~ 7 ~ ~  
I ~ TATA I 
L.~x 
ActJvation 
C gall 1- celts 
/ J 
I ~Le~x TATA I 
Activation 
( * GALl 1 as well as GAL 11P ) 
Figure 8. Potentiation by GALl 1P and Activation by GALl 1 Tethered 
to DNA 
(A) A DNA-bound molecule fused to GAL4(58-97) does not activate 
transcription in GAL 11 wild-type cells. GALl 1 and a subset of the other 
components that comprise RNA polymerase II holoenzyme are shown. 
Transcription factors TFIID and TFIIE, which are not part of the holoen- 
zyme described by Koleske and Young (1994), are not shown. 
(B) GAL4(58-97) works as an activating region in GAL11P cells be- 
cause it specifically interacts with GALl 1P and thereby recruits the 
RNA polymerase II holoenzyme complex to the promoter. 
(C) A sequence-specific DNA-binding module fused to GALll(or to 
GALl 1 P) recruits the holoenzyme to the promoter and activates tran- 
scription. 
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the site on GALl 1 that mutates to GALl 1P lies in a func- 
tionally inert part of the protein. To our knowledge, there 
is no special significance to the fact that GALl 1 contains 
the mutation that creates a new target for an otherwise 
inactive activating region, other than that GALl1 is part 
of the holoenzyme. The recruitment model is further sup- 
ported by the fact that tethering GALl 1 to DNA by fusion 
to a DNA-binding domain induces strong activation, and 
that the part of GALl 1 that works as an activating region 
in this scenario contacts other components of the holoen- 
zyme. The results presented in this paper more broadly 
raise the possibility that natural activators also work by 
recruitment as well (see below). 
Our results suggest that interaction between a DNA- 
bound protein and a single component of the holoenzyme 
is sufficient to trigger gene activation, at least at the follow- 
ing four yeast promoters: GALl, CYC1 (not shown), GAL80 
(not shown), and HIS3 (not shown). It is hard for us to 
imagine, for example, that GAL4 residues 58-97 contact 
various components of the transcriptional machinery but 
work as an activating region only in GAL11P cells. If our 
line of reasoning is correct, strong activation does not, for 
example, require direct interaction of the activating region 
with machinery that helps remove nucleosomes. If such 
a machinery, e.g., the SNF/SWl complex (Kwon et al., 
1994; C6te et al., 1994), is required under our conditions, 
it might work constitutively toallow the transcriptional com- 
ponents to compete for access to DNA, or it might be 
brought o the DNA by interaction with some component 
of the transcriptional machinery. 
The model of Figure 8 omits at least one important com- 
ponent of the transcriptional machinery, TFIID. We sus- 
pect that TFIID is indeed required for activation by 
GAL4(58-97) in GAL11P cells, and by LexA-GAL11, be- 
cause in both instances, mutation of the TFIID-binding 
site (TATA) greatly decreased activation (data not shown). 
Recent experiments uggest that TFIID is not part of the 
holoenzyme, although an earlier report suggested it might 
be (Koleske and Young, 1994; Thompson et al., 1993). 
We imagine that required components that are not part 
of the holoenzyme bind to DNA prior to recruitment of the 
holoenzyme or bind cooperatively with the latter when it 
is recruited in our experiments. For example, others have 
argued that TFIID is bound at the CYC1 promoter prior to 
activation (Chen et al., 1994), but that TFIID binds concom- 
itantly with activation at the GALl and HIS3 promoters 
(Selleck and Majors, 1987; Klein and Struhl, 1994); as 
mentioned above, we observe activation by contact with 
the holoenzyme at all of these promoters. Two forms of 
the holoenzyme lacking TBP have been described. 
Koleske and Young (1994) isolated a complex that in- 
cludes, in addition to RNA polymerase and several SRB 
proteins, the transcription factors TFIIB, TFIIH, and TFIIF; 
our experiments how that GALl 1 is also part of this com- 
plex. Kim et al. (1994) described a complex of RNA poly- 
merase II with a so-called mediator component hat in- 
cludes GALl1 but does not include TFIIB and TFIIH, and 
they showed that, in vitro, optimal transcription requires 
this mediator. 
As mentioned in the Introduction, several different clas- 
sical activator-transcription factor interactions have been 
described. To explain this plethora of interactions, Koleske 
and Young (1994) and Carey (1994) have proposed that 
activators can recruit he holoenzyme to DNA and thereby 
activate transcription by contacting one or another of sev- 
eral potential sites on the surface of the holoenzyme. Our 
results are consistent with that idea. We might further ex- 
tend the idea by noting that two of the activating region 
targets listed in the Introduction are part of the TFIID com- 
plex (TBP and TAFs), and two are part of the holoenzyme 
as described by Koleske and Young (1994) (TFIIB and 
TFIIH). If the holoenzyme binds cooperatively to DNA with 
other transcriptional components (e.g., TFIID), then acti- 
vation might be triggered by interaction of an activating 
region with any of those components. It is conceivable that 
promoters differ in their affinities for different components, 
such that activator contact with one or another complex 
(e.g., TFIID or the holoenzyme), or both, is required for 
gene activation in any given case; activating regions that 
touch multiple components would be expected to work at 
many promoters. This general line of reasoning suggests 
that the many different activator-target interactions re- 
ported could each be biologically relevant. 
The idea that activators can interact with different sur- 
faces of the holoenzyme (or of TFIID) parallels our under- 
standing of gene activation in Escherichia coll. There the 
bacterial polymerase, a multimer of subunits (~, 13, 13', and 
(~2, is isolated as the holoenzyme under one set of condi- 
tions and as core enzyme (lacking o) under another (Bur- 
gess et al., 1969), and both (~ and the core have been 
identified as targets of activators: X repressor (working as 
an activator) is believed to contact a, and catabolite gene 
activator protein (CAP) contacts ~ (Li et al., 1994; Chen 
et al., 1994). Moreover, recent experiments uggest that 
there may be several sites on (~, contact with any one of 
which suffices to recruit polymerase to DNA and activate 
transcription (Ishihawa, 1993). Joung et al. (1994) have 
shown that ;~ repressor and CAP, bound to adjacent sites 
on DNA near a promoter, activate that promoter synergisti- 
cally, evidently because two different surfaces of the poly- 
merase holoenzyme are contacted by the two activators. 
It has been suggested that synergistic activation in eukary- 
otes requires interaction of activating regions with two or 
more targets (Carey et al., 1990). 
We know from examples in prokaryotes (e.g., activation 
of transcription by ;L repressor) that very weak protein- 
protein interactions (in this case between X repressor and 
E. coil RNA polymerase) can trigger gene activation 
(Ptashne, 1992). These weak interactions nevertheless 
have significant effects when the interacting components 
are binding cooperatively to DNA. The interaction we mea- 
sure between GAL11P and GAL4(1-100) has a Kd of 
roughly 10 -7 M, as calculated from BIAcore data (Y. Wu, 
A. B., and M. P., unpublished ata). Our experiments indi- 
cate that interactions of this order of affinity suffice for 
strong gene activation in yeast, and they suggest hat bona 
fide activating regions might interact with their targets with 
similar affinities. 
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Experimental Procedures 
Genetic Methods 
Cells were grown and assayed for ~-galactosidase activity as de- 
scribed by Rose et al. (1990). In all the figures of this paper, the num- 
bers listed are the averages of three or more independent experiments; 
the standard error for cultures assayed in triplicate was less than 20%. 
Plasmids expressing deletion derivatives and fusion proteins were 
constructed by use of convenient restriction sites or by the polymerase 
chain reaction (PCR) using Pfu polymerase (Stratagene). Details of 
plasmid and strain construction are available upon request. Mutagene- 
sis of a portion of the GAL4 dimerization domain for the experiment 
shown in Figure 3C was performed by chemical saturation mutagene- 
sis as described by Myers et al. (1985). 
Yeast Extracts and Immunoassays 
Whole-cell extacts were prepared according to the protocol of Woont- 
ner et al. (1991), and nuclear extracts were prepared as described 
by Lue and Kornberg (1987). Immunoprecipitation and Western blot 
assays were performed as described by Harlow and Lane (1988). 
Protein Purification 
Mini-GALl 1 (261-351)+(799-1081 ), with or without the P mutation at 
residue 342, was tagged with six His residues and a Myc epitope 
(EQKLISEEDL) at its amino terminus and expressed in the yeast strain 
JELl (MATa leu2 trpl ura3-52 prb1-1122 pep4-3 •His3::pGALIO- 
GAL4, a gift of J. Lindsley) from the inducible GALl promoter on a 
high copy plasmid (LEU2 2~). Yeast cells carrying the mini-GALl1 
expression plasmid were grown to saturation in 300 ml of selective 
medium containing 2% (w/v) glucose. This culture was used to inocu- 
late 6 liters of selective medium containing 5% (w/v) glycerol. Cells 
were allowed to grow for 12-14 hr prior to the addition of galactose 
to a final concentration of 2% (w/v). After an 8 hr incubation, cells were 
collected by centfifugation and washed once in cold water. Whole-cell 
extracts were prepared as described by Woontner et al. (1991) and 
loaded on a 5 ml nickel-agarose column (Qiagen). After two rounds 
of extensive washing with, first, 10 mM imidazole in loading buffer 
(0.2 M Tris [pH 7.9], 0.39 M (NH4)~SO4, 10 mM MgSO4, 20% glycerol, 
1.4 mM 2-mercaptoethanol, 0.1% Tween 20, and the following prote- 
ase inhibitors: 1 mM phenylmethylsulfonyl fluoride, 0.2 mM benzami- 
dine hydrochloride, 10 mM bestatin, 2 mM leupeptin, 2 mM pepstatin) 
and, second, 1 M urea in buffer NiD (20 mM Tris [pH 7.9], 100 mM 
KCI, 20% glycerol, 1.4 mM 2-mercaptoethanol, and the same protease 
inhibitors as in the loading buffer), tagged mini-GALl 1 proteins were 
eluted with a gradient of imidazole (10 mM-250 mM) in buffer NiD. 
All operations were performed at 4°C and monitored by an ultraviolet 
detector (Gilson). Fractions containing mini-GALl1 were pooled and 
extensively dialysed against buffer NiD. GAL4 derivatives and other 
DNA-binding proteins assayed in this study were expressed in bacteria 
and purified as described by Reece and Ptashne (1993). 
Protein Binding Assays 
Surface plasmon resonance measurements were performed in a BIA- 
core instrument from Pharmacia Biosensor AB. BIAcore sensor chips 
(Pharmacia) were modified to bind His-tagged proteins by adsorbing 
a mixed monolayer of thiols presenting NF + bound to a nitrilotriacetic 
acid derivative on the gold surface. A description of the sensor chip 
preparation will appear elsewhere (G. S., C. B., A. B., J. Strominger, 
and G. Whitesides, unpublished data). The procedure involves a 5 ~_1/ 
min continuous flow of buffer (HEPES-buffered saline: 10 mM HEPES 
[pH 7.4], 150 mM NaCI) over the chip surface interrupted by 7 rain 
protein injections. All experiments were performed at room tempera- 
ture, and His-tagged proteins stably bound to the chip surface without 
further modification. 
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